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Abstract
Background: Apart from the mean level of glycemic control, the extent of glucose excursions is another important
issue to consider in type 2 diabetes mellitus (T2DM) management. Studies have showed that fluctuations of glucose
seem to have more deleterious effects than sustained hyperglycemia in the development of diabetic complications as
acute glucose swings activate the oxidative stress. However, until now, no randomized controlled trials have been
conducted with the primary aim to evaluate glycemic fluctuation in the comparison between twice-daily exenatide
and other treatment paradigms (for example, biphasic insulin aspart 30).
Methods/design: This multicenter, open-label, randomized, parallel trial includes a 1-week screening period and a
16-week treatment period. After the screening period, 150 patients with confirmed type 2 diabetes who are treated with
stable, maximum-tolerated doses of metformin will be randomly assigned to one of two groups for antihyperglycemic
therapies: exenatide and biphasic insulin aspart 30. The treatment with exenatide will be initiated at a low dose of 5 μg
twice a day for 4 weeks and then titrated up to a standard dose of 10 ug twice a day until the completion of the study.
The adjustment of insulin dose is instructed to achieve an optimal balance between glycemic control and the risk of
hypoglycemia as dictated by clinical practice. The primary outcome is the absolute change of mean amplitude of
glycemic excursion from baseline to week 16, which is calculated based on a real-time continuous glucose monitoring
system (CGMS).
Discussion: This is the first randomized controlled trial using a CGMS to evaluate glycemic fluctuation between
twice-daily exenatide and insulin aspart 30, which will provide beneficial evidence of exenatide usage in patients
with T2DM.
Trial registration number: NCT02449603. Date of registration: 11 May 2015.
Background
Due to the rapid change in the Western diet and seden-
tary lifestyle, China has become one of the countries
with the largest number of people suffering from diabetes
in the world. The most recent two nationwide diabetes
surveys indicated that the prevalence of type 2 diabetes
mellitus (T2DM) has reached 9.7 % and 11.6 % [1, 2],
translating into 92.4 million and 113.9 million patients in
China [1, 2], respectively.
Uncontrolled T2DM is associated with long-term
microvascular complications, such as retinopathy, ne-
phropathy, and neuropathy, as well as cardiovascular
events that are dangerous and even fatal. Strict glucose
management is thus required. In current clinical practice
guidelines, the first-line medication for T2DM is metfor-
min. When oral therapies fail to provide adequate glycemic
control, the common treatment paradigm is to initiate
insulin therapy [3] such as biphasic insulin aspart 30.
For example, nearly 70 % of Chinese patients who are initi-
ating insulin therapy choose premixed insulin [4]. Previous
studies have shown that, in combination with metformin,
twice-daily biphasic insulin aspart 30 before breakfast and
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dinner improves glycemic control more than metformin
plus glyburide or biphasic insulin aspart 30 alone [5].
An emerging treatment option for patients failing to re-
spond to oral antidiabetic drugs is glucagon-like peptide-1
receptor agonist (GLP-1RA) [3]. Exenatide is an incretin
mimetic that shares several glucoregulatory actions with
the incretin glucagon-like peptide-1, including the enhance-
ment of glucose-dependent insulin secretion, the suppres-
sion of inappropriately elevated postprandial glucagon
secretion, the reduction of food intake, and the slowing of
gastric emptying [6, 7]. Placebo-controlled studies have
shown that exenatide-treated T2DM patients that are sub-
optimally controlled with oral glucose-lowering agents
can exhibit improved glycemic control, together with the
additional benefit of sustained weight reduction [8–12].
Apart from the mean level of glycemic control, the ex-
tent of glucose excursions is another important issue in
T2DM management. Some studies have shown that glu-
cose fluctuations seem to have more deleterious effects
than sustained hyperglycemia in the development of dia-
betic complications as acute glucose swings activate oxi-
dative stress [13, 14]. Recent studies have indicated that
glycemic variability might play a role in the pathogenesis
of atherosclerosis and may be an independent risk factor
for cardiovascular complications in diabetic patients [15].
Previous studies have also suggested that exenatide may
provide a better improvement of glucose variability with
similar glycemic control than insulin aspart 30 [16].
However, until now, no randomized controlled trial has
been conducted with the primary aim to evaluate glycemic
fluctuation in the comparison between twice-daily exena-
tide and other treatment paradigms (for example, biphasic
insulin aspart 30).
This randomized controlled study aimed to demonstrate
whether exenatide, compared to biphasic insulin aspart
30, could provide a superior improvement of glycemic ex-
cursion (assessed by continuing glucose monitor system
(CGMS)) and a better improvement of inflammatory and
oxidative stress markers after a 16-week treatment in
Chinese T2DM patients who failed to improve on metfor-
min monotherapy.
Methods/design
This multicenter, open-label, randomized, parallel trial,
which includes a 1-week screening period and a 16-week
treatment period, is planned to start in June 2015 and
complete in September 2016.
Location and setting
Eight study sites will be involved in the multicenter
study, including Xijing Hospital, Fourth Military Medical
University (Xi’an, China), the First Affiliated Hospital of
Xi’an Jiaotong University (Xi’an, China), the Second Af-
filiated Hospital of Xi’an Jiaotong University (Xi’an, China),
Shaanxi Provincial People’s Hospital (Xi’an, China), Chang
An Hospital (Xi’an, China), Xi’an Gaoxin Hospital (Xi’an,
China), Xi’an Central Hospital (Xi’an, China) and Shaanxi
Aerospace Hospital (Xi’an, China).
Study population and eligibility criteria
A total of 150 subjects will be enrolled. Subjects should
fulfil the following criteria:
1. Provide informed consent prior to any study specific
procedures.
2. Men and women (nonpregnant and using a medically
approved birth-control method) between 18 and
70 years of age at screening.
3. Confirmed type 2 diabetes with history of at least
half a year.
4. Treatment with stable, maximum-tolerated doses of
metformin (≥1500 mg/d, ≥ 3 months).
5. HbA1c ≥ 7.5 % and ≤ 10.0 % at screening or within
4 weeks prior to screening (by local laboratory).
6. Body mass index: 21 to 35 kg/m2.
Subjects should not enter the study if any of the
exclusion criteria in Appendix 1 are fulfilled.
Interventions
The trial will include a 1-week screening period of stable
doses of metformin (1500 mg) and a 16-week treatment
period. Patient will take the first dose after randomization
on Day 1. The investigational products of exenatide and
biphasic insulin aspart 30 will be administered through
subcutaneous injection. The background product of met-
formin will be taken orally at 500 mg three time daily until
the completion of the study.
Exenatide (AstraZeneca) should be initiated, 60 minutes
before breakfast and before dinner, at a low dose of 5 ug
twice a day for 4 weeks and then titrated up to a standard
dose of 10 ug twice a day until the completion of the
study.
Biphasic insulin aspart 30 (Novo Nordisk) will be started
at a dose of 0.2 to 0.4 IU/kg, or 10 to 12 IU/d, assigned to
before breakfast or before dinner in a 1:1 ratio. The adjust-
ment of the insulin dose will be instructed to achieve an
optimal balance between glycemic control and the risk of
hypoglycemia as dictated by clinical practice. It will be ti-
trated to glucose targets of fasting plasma glucose (FPG)
and predinner plasma glucose < 7 mmol/L. Insulin dose ti-
tration will be based on the average self-monitored blood
glucose (SMBG) results for 3 days preceding visits, unless
hypoglycemia occurs. If hypoglycemia occurs, titration
will be temporarily postponed, and the reasons of
hypoglycemia will be evaluated. Subjects could not in-
crease the total daily dose by more than 10 U at any
time. After visit 2 (week 0), insulin doses will be titrated
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weekly for the first 12 weeks, then every 2 weeks there-
after according to the titration algorithm (Table 1).
Outcomes
The primary and secondary outcomes are shown in
Table 2.
Participant timeline
The time schedule for the enrollment, interventions, as-
sessments, and visits for participants are shown in Table 3.
Sample size estimate
This study is a pilot study, which is planning to recruit
150 patients. This sample size is a justification from stat-
istical considerations as follows:
The hypothesis on the primary endpoint is to test the
mean amplitude of glycemic excursion (MAGE) in exena-
tide group superior to aspart 30 group. According to the lit-
erature review and previous studies, the standard deviation
(SD) of change of MAGE is conservatively estimated as
3.0 mmol/L (in a pilot study of exenatide, the SD of MAGE
is 2.7 to 3.1 mmol/L) [17]. With a two-sided 0.05 alpha level
and a 15 % dropout rate, 150 patients with a 1:1 allocation
rate (75 patients per group) will offer at least 85 % power to
test a minimum 1.6 mmol/L difference on the change of
MAGE between the exenatide and aspart 30 groups.
Assignment of interventions
Patients will be randomized 1:1 to treatment groups via
a central randomization system (interactive voice/web
response system (IVRS/IWRS)), and the drug will be dis-
pensed accordingly. The study population will be stratified
at randomization based on MAGE (<5.6 mmol/l and ≥
5.6 mmol/l) and the severity of the disease (HbA1c < 9.0 %
and ≥ 9.0 %).
Because the study drug (Exenatide) has an obviously dif-
ferent appearance from, and is used differently from, the
biphasic insulin aspart 30, a definite blindness is hard and
worthless for investigators and patients. Therefore, an
open-label study is being conducted. Bias at randomization
is reduced by the use of a central randomization system.
Moreover, key efficacy parameters (MAGE, HbA1c, FPG,
and postprandial plasma glucose (PPG)) will be blinded for
the investigator during the course of the study (from
randomization to week 16) except for the screening and
pre-randomization visit. However, when FPG meets the
study drug discontinuation criterion of hyperglycemia,
the investigator will be alerted to conduct retest for
confirmation.
Data collection and management
The laboratory parameters that will be measured to as-
sess efficacy and safety at each visit are shown in Table 3.
Blood samples for efficacy and safety assessments will be
performed on the days of the specified visits in a fasted
condition (expect 2-h PPG), prior to administration of
study treatment (patients must not take study drug at
home on the day of the study visit but must bring it to the
study center). Blood sample for 2-h PPG testing will be
drawn at 120 min after the first intake of standard meal
during the standard meal testing on the days of the speci-
fied visits. All blood samples for efficacy assessments in
the study will be sent to the central lab for analysis. The
blood and urine samples for safety assessments will be
performed at local laboratories.
Blood glucose (BG) is monitored in the study sites by
a Guardian™ Real-Time CGMS (Medtronic MiniMed
Inc., CA, USA), which is used to record glucose levels
every 5 min for 72 h consecutively. During the second
visit (baseline visit) and the last visit (end of the study),
the continuous glucose sensor is inserted subcutaneously
in the abdominal periumbilical area, separately. Meanwhile,
a blood glucose meter is used to perform sensor calibration
four times daily. The participants receive a calibration
2 hours after sensor insertion and then four glucose cali-
brations at each meal and before bed, and the time of each
meal is marked in the consecutive 3-day test. Participants
are provided the same mixed meals (30 kcal/kg ideal
weight/day, based on dietitian recommendations, including
55 % of calories from carbohydrates, 25 % from fat and
20 % from proteins, with a meal distribution of 1/5, 2/5
and 2/5). They must keep a diary of meals (content and
times) and avoid intensive physical activity during both
CGMS periods. The dietary pattern using 3-day diet
records for each CGMS study period will be checked
in all participants. All the parameters of continuous
glucose monitoring are calculated from each CGMS
output, which is extracted using the CGMS 3.0 soft-
ware package (Medtronic MiniMed, MMT-7310 version
3.0C (3.0.128), CA, USA). The mean glucose level is calcu-
lated as the mean of all the consecutive sensor readings,
from which the SD is also calculated. The largest ampli-
tude of glycemic excursion (LAGE) is defined as the
Table 1 Prebreakfast and predinner insulin titration regimens
Fasting and/or predinner SMBG PG value (mmol/L) Adjustment
<5.0 -2 U
5.0 to 7.0 No adjustment
7.1 to 7.7 +2 U
7.8 to 10 +4 U
>10 +6 U
BG, blood glucose; SMGB, self-monitored blood glucose
Glycemic targets for titration: Prebreakfast and predinner PG: 5.0 to 7.0 mmol/L.
Prebreakfast dose of biphasic insulin aspart 30 is titrated based on the three
mean predinner PG values for the 3 days prior to the visit. Predinner dose of
biphasic insulin aspart 30 is titrated based on the three mean fasting PG
values for the 3 days prior to the visit. The predinner biphasic insulin aspart
30 titration is not increased if the preceding day’s bedtime SMGB value
is 5.6 mmol/L
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maximal sensor glucose level minus the minimal sensor
glucose level during each day. The MAGE is used for
assessing the intraday glucose variability. MAGE is calcu-
lated by measuring the arithmetic mean of the differences
in consecutive peaks and nadirs, which are taken into con-
sideration only if they exceed one standard of deviation
from the mean [18]. The mean of the daily differences
(MODD), calculated as the average absolute difference of
paired sensor glucose values during two successive 24-h
periods, is used to assess the interday glucose variability.
Instant noodles are used as a standard meal, which in-
cludes 85 g of instant noodle equivalent to an energy in-
take of 500 kilocalories. The procedures for standard
meal test are described in Table 4. The fasting plasma
glucose will be tested at visits 1 to 6. HbA1c, fasting
C-peptide and 2-h PPG will be tested at visit 1, 2 and
6. The baseline is defined as the assessment at Visit 2.
The samples are collected after fasting for 12 hours for
fasting plasma glucose, fasting C-peptide and HbA1c.
Then the participants will be given 85-gram instant
noodles and asked to eat up in 8 minutes at visit 2 and
visit 6. Two hours later, blood samples will be collected
again for plasma glucose.
Physical examination, electrocardiogram, vital signs,
and other safety assessments also will be performed using
standard methods. Since the two study drugs (exenatide
and biphasic insulin aspart 30) are two well-described safe
antihyperglycemic medications, and our treatment period
is only 16 weeks, some of the safety assessments, like
urinalysis, liver function, creatinine, and blood urea nitro-
gen, are tested only at the baseline and the 16-week safety
assessment. Adverse events during all the study period will
be collected.
Statistical methods
The primary analysis population will be based on the full
analysis set (FAS) and will include all randomized patients,
according to the intention-to-treat (ITT) basis. All sup-
portive analyses will be based on per-protocol set (PPS)
analysis set, and the safety endpoints will be analyzed on
safety analysis set (SS). The research has no plans to im-
plement interim analysis.
All data will be entered into SPSS 10.0 software (SPSS
Inc., Chicago, IL). Analyses by actual therapy include only
those patients who are continuing to take their allocated
therapy. Data are presented as mean and SD, range, or
percentage. Data will be examined for skewness, out-
liers, and systematic missing data. Transformations will
be undertaken as needed. Univariate and multivariate
tests for repeated measures (ANOVA) are used to evaluate
differences within and between groups over time. Mann–
Whitney U test is used to evaluate differences between
groups, whereas Friedman’s test (variance analysis) followed
by Wilcoxon paired test is used to evaluate differences
within groups. P < 0.05 is considered significant.
All efficacy endpoints will be analyzed in FAS, using a
covariance model. Point estimates and SD for the mean
change within each treatment group will be estimated.
Table 2 Primary and secondary outcomes
Outcome measure:
Primary outcome
To compare the effect of exenatide versus biphasic insulin aspart 30 on
glucose variability in T2DM patients inadequately controlled with
metformin monotherapy.
Absolute change of MAGE from baseline to Week 16
Secondary outcome
To compare the effect of exenatide versus biphasic insulin aspart 30 on
inflammatory and oxidative stress markers, HbA1c, weight, risk of
hypoglycemia and cardiovascular risk markers.
HbA1c at baseline and Week 16
Hours of hypoglycemia assessing by CGMS at baseline and Week 16
SMBG at baseline and Week 16
Blood pressure and lipids at baseline and Week 16
Body weight, BMI and WC at baseline and Week 16
Inflammatory markers (MCP-1, hs-CRP) at baseline and Week 16
Urinary albumin at baseline and Week 16
Safety outcome
To evaluate the safety and tolerability of exenatide in relation to biphasic
insulin aspart 30.
Adverse events/serious adverse events
Vital signs
Clinical hypoglycemia
Collection of clinical chemistry/hematology parameters
Electrocardiogram
T2DM, type 2 diabetes mellitus; MAGE, mean amplitude of glycemic excursion; CGMS, continuous glucose monitoring system; BMI, body mass index; WC, waist
circumference; MCP-1, monocyte chemotactic protein-1; hs-CRP, high-sensitivity C-reactive protein
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Table 3 Study plan detailing the procedures
Study Period Screening Treatment
Visit V1 V2 V3 V4 V5 V6 V7 V8 V9
Randomization
Week −1 0 (baseline) 1 2 4 8 10 12 16
Day 0 ±2 ±2 ±7 ±7 ±2 ±7 ±7
Telephone visit × × ×
Screening/baseline
Written informed consent ×
Inclusion/exclusion criteria × ×
Demographics ×
Physical examination × × × × × ×
Medical/current conditions × × × × × × × × ×
History of diabetes & complications ×
Lifestyle instruction × × × × × × × × ×
Treatment
Drug dispensing and accountability × × × ×
Concomitant medications × × × × × × × × ×
SMBG × × × × × × ×
Insulin titration × × × × × ×
Safety assessments
Pregnancy test (urine) × ×
Physical examination × × × × × ×
Vital signs × × × × × ×
12-lead ECG × ×
Hematology panel × ×
Urinalysis × ×
Liver function × ×
Creatinine, BUN, uric acid × ×
Lipids × × ×
Adverse events × × × × × × × ×
Efficacy assessments
HbA1c × ×
Fasting plasma glucose × × × × × ×
Fasting insulin and C-peptide × ×
CGMS × ×
Standard meal test:2 h PPG, insulin and C-peptide × ×
BW, BMI and WC × × × × × ×
Other assessment
MCP-1, hs-CRP × ×
8-Iso-PGF2α × ×
Urinary albumin × ×
SMBG, self-monitoring of blood glucose; ECG, electrocardiogram; BUN, blood urea nitrogen; CGMS, continuous glucose monitoring system; PPG, postprandial
plasma glucose; BW, body weight; BMI, body mass index; WC, waist circumference; MCP-1, monocyte chemotactic protein-1; hs-CPR, high-sensitivity C-reactive
protein; 8-Iso-PGF2α, 8-Iso-prostaglandin F2α
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Difference within and between groups over time will be
analyzed using covariance test. A last observation carried
forward (LOCF) analysis will be presented for each effi-
cacy assessment as sensitivity analysis unless otherwise
specified.
The safety endpoints will be analyzed on SS. Adverse
events will be summarized. The incidence of adverse
events will be summarized by body system organ class
and preferred term. Analyses for safety and tolerability
endpoints will be summarized using descriptive statistics
for continuous variables or frequency counts and per-
centages for categorical variables.
Ethics and dissemination
The trial was approved by the Independent Ethics
Committee, First Affiliated Hospital of Fourth Military
Medical University (ID: KY20150319, KY20150505-1)
and was registered (registration date: 11 May 2015) in
the United States National Institutes of Health Clinical
Trials Registry (ClinicalTrials.gov, identifier: NCT02449603).
The study will be supervised by Excellence Future Inter-
national Consulting Co., Ltd. The findings of this trial
will be submitted to a peer-reviewed journal. Abstracts
will be submitted to relevant national and international
conferences.
Each subject will provide signed and dated informed
consent before conducting any procedure specifically for
the study. Participation in this study is strictly confiden-
tial. Any information that is published will not reveal the
identity of the subjects.
Discussion
An unmet need exists for diabetes research with
interest in glucose variability assessed by CGMS, as
glucose variability is suggested to lead to the develop-
ment of long-term complications [19] and MAGE
assessed by CGMS is the “gold standard” to evaluate
glucose variability.
In American Diabetes Association (ADA), European As-
sociation for the Study of Diabetes (EASD), and Chinese
Diabetes Society (CDS) guidelines, both insulin and
GLP-1 RA could be the initial option when oral therap-
ies fail to provide adequate glycemic control, and nearly
70 % Chinese patients choose premixed insulin as the
initial insulin therapy [4].
Previous studied have demonstrated that, compared
with insulin aspart 30, exenatide showed a better effect
on glycemic fluctuation assessed by seven-point SMBG
with similar glycemic control and lower risk of hypoglycemic
[16, 20]. For example, in a 52-week, open-label, non-
inferiority trial, patients failing to reach treatment goals
with metformin and sulphonylurea were randomized to
exenatide (n = 253; 5 μg twice daily (BID) 4 weeks, 10 μg
thereafter) or premixed insulin (n = 248; BID doses titrated
for optimal glucose control). The results demonstrated that
exenatide BID has a similar glycemic effect to insulin
aspart 30 assessed with HbA1c in T2DM patients. More im-
portantly, the results demonstrated that exenatide-treated
patients had significantly greater reductions in postprandial
glucose excursions (the difference between preprandial
and postprandial plasma glucose levels) following the
morning (P < 0.001), midday (P < 0.002), and evening meals
(P < 0.001) than patients treated with premixed insulin
assessed with seven-point SMBG [16]. However, in these
studies, MAGE was not the primary endpoint, or CGMS
was not used.
The statistically significant and clinically relevant re-
duction on glucose variability with exenatide was associ-
ated with the profile of safety and tolerability superior to
biphasic insulin aspart 30. Data establishing the clinical
efficacy of exenatide are based on two core Phase 3 studies:
one glimepiride-controlled pilot study with glycemic vari-
ability assessed by CGMS, which only included 12 patients
[17], and one biphasic insulin aspart 30-controlled study,
where glycemic excursion was assessed by SMBG [16].
The key results of these studies were that treatment
with exenatide resulted in consistent, clinically mean-
ingful, and statistically significant greater reductions in
glucose excursions, in addition to being associated
with non-inferior glycemic control relative to the ac-
tive comparator.
This is the first randomized controlled trial using
CGMS to evaluate glycemic fluctuation between twice-
daily exenatide and insulin aspart 30, which will pro-
vide beneficial evidence to exenatide usage in patients
with T2DM.
Trial status
This trial is currently ongoing and actively recruiting
patients. The first participant was enrolled on 10
December 2015.
Table 4 Overview of standard meal test assessments
Time Assessment
-15 ± 5 min Blood sampling for plasma glucose,
insulin, and C-peptide testing
-15 ± 5 min Administer metformin and exenatide
(or biphasic insulin aspart 30)
0 min Start of ingestion standard meal
+8 ± 2 min End of ingestion standard meal
+120 ± 10 min Blood sampling for plasma glucose,
insulin, and C-peptide testing
All time points are relative to targeted first mouthful of the standard meal,
at Time 0
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Appendix 1
Exclusion criteria
1. Women who are pregnant, intending to become
pregnant during the study period, currently lactating
females, or women of child-bearing potential not
using highly effective, medically approved birth
control methods.
2. Diagnosis or history of a) type 1 diabetes mellitus,
diabetes resulting from pancreatic injury, or secondary
forms of diabetes, for example, acromegaly or
Cushing’s syndrome. b. Acute metabolic diabetic
complications such as ketoacidosis or hyperosmolar
coma within the past 6 months.
3. Previous treatment with any dipeptide peptidase-4
(DPP4) inhibitor or GLP-1 receptor agonists within
the past year.
4. History of hypersensitivity reaction (for example,
anaphylaxis, angioedema, or exfoliative skin conditions)
to dipeptide peptidase-4 inhibitor (DPP4) or acarbose.
5. Treatment with any antidiabetic medication for more
than 7 consecutive days other than metformin in the
3 months prior to screening.
6. Treatment with systemic glucocorticoids (oral or
intravenous) for more than 7 consecutive days within
the past 6 months.
7. Triglycerides (fasting) > 4.5 mmol/L (>400 mg/dL)
at screening or within 4 weeks prior to screening
(by local laboratory).
8. Patients with clinically apparent liver disease
characterized by either of the following: a) ALT or
AST > 3x upper limit of normal (ULN) confirmed on
two consecutive measurements (by local laboratory)
within 4 weeks prior to screening period; b) impaired
excretory (for example, hyperbilirubinemia) and/
or synthetic function, or other conditions of
decompensated liver disease such as coagulopathy,
hepatic encephalopathy, hypoalbuminemia, ascites
and bleeding from esophageal varices; or c) acute
viral or active autoimmune, alcoholic, or other types
of hepatitis.
9. Patients with moderate/severe renal impairment
or end-stage renal disease (estimated glomerular
filtration rate ≤ 60 mL/min calculated by using the
abbreviated equation developed by the Modification
of Diet in Renal Disease (MDRD) study with
modification for the Chinese population) at screening
or within 4 weeks prior to screening (by local
laboratory).
10. Congestive heart failure defined as New York
Heart Association (NYHA) class III or IV.
11. Significant cardiovascular history within the
3 months prior to screening, defined as myocardial
infarction, coronary angioplasty or bypass graft(s),
valvular disease or repair, unstable angina pectoris,
transient ischemic attack, or cerebrovascular accident.
12. History of chronic pancreatitis or idiopathic acute
pancreatitis.
13. History of gastrointestinal disease, including
gastroenterostomy, enterectomy, Roemheld Syndrome,
severe hernia, intestinal obstruction, or intestinal ulcer.
14. History of genetic galactose intolerance, Lapp lactase
deficiency, and glucose-galactose malabsorption.
15. History of medullary thyroid carcinoma.
16. Diagnosed and/or treated malignancy (except for
basal cell skin cancer, in situ carcinoma of the cervix,
or in situ prostate cancer) within the past 5 years.
17. History of organ transplant or acquired
immunodeficiency syndrome (AIDS).
18. History of alcohol abuse or illegal drug abuse
within the past 12 months.
19. Potentially unreliable patients and those judged by
the Investigator to be unsuitable for the study.
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